Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linagliptin - Boehringer Ingelheim/Eli Lilly and Company

Drug Profile

Linagliptin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI 1356; BI 1356 BS; Dipeptidyl peptidase IV inhibitor - Boehringer Ingelheim; Ondero; Tradjenta; Trajenta; Trayenta; Trazenta

Latest Information Update: 14 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies

Most Recent Events

  • 11 Jun 2019 Efficacy data from the phase III CAROLINA trial in Type-2 diabetes mellitus presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
  • 10 Jun 2019 Adverse events data from the phase-III CAROLINA trial in Type-2 diabetes mellitus presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
  • 14 Mar 2019 Boehringer Ingelheim completes a phase II trial in Type-2 diabetes mellitus in Japan (PO) (UMIN000014864)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top